DURECT Corporation (DRRX)

Etorro trading 970x250
DURECT Corporation (DRRX) Logo

About DURECT Corporation

DURECT Corporation, a biopharmaceutical company, researches and develops medicines based on its epigenetic regulator and pharmaceutical programs. The company offers ALZET product line that consists of osmotic pumps and accessories used for research in mice, rats, and other laboratory animals. It also develops DUR-928, an endogenous, orally bioavailable small molecule that is in Phase IIb clinical trial to play a regulatory role in lipid homeostasis, inflammation, and cell survival, as well as completed Phase Ib clinical trial to treat patients with nonalcoholic steatohepatitis. In addition, the company offers POSIMIR, a post-surgical pain product to deliver bupivacaine up to days of in adults. It markets and sells its ALZET lines through direct sales force in the United States, as well as through a network of distributors in Japan, Europe, and internationally. The company has strategic collaboration and other agreements with Virginia Commonwealth University Intellectual Property Foundation; Indivior UK Ltd.; Santen Pharmaceutical Co., Ltd.; Sandoz AG; and Gilead Sciences, Inc. DURECT Corporation was incorporated in 1998 and is headquartered in Cupertino, California. Address: 10260 Bubb Road, Cupertino, CA, United States, 95014-4166

DURECT Corporation News and around…

Latest news about DURECT Corporation (DRRX) common stock and company :

12 Health Care Stocks Moving In Thursday's After-Market Session
13 Jan, 2022 FinancialContent

Gainers Stealth BioTherapeutics (NASDAQ:MITO) stock increased by 11.7% to $0.97 during Thursday's after-market session. The company's ...

Here's Why Durect (DRRX) is Poised for a Turnaround After Losing 17.1% in 4 Weeks
13 Jan, 2022 Yahoo! Finance

Durect (DRRX) is technically in oversold territory now, so the heavy selling pressure might have exhausted. This along with strong agreement among Wall Street analysts in raising earnings estimates could lead to a trend reversal for the stock.

12 Health Care Stocks Moving In Wednesday's After-Market Session
12 Jan, 2022 FinancialContent

Gainers Biomerica (NASDAQ:BMRA) stock increased by 10.2% to $4.95 during Wednesday's after-market session. The market value of their ...

DURECT Corporation to Participate in H.C. Wainwright Bioconnect Conference
06 Jan, 2022 Yahoo! Finance

DURECT Corporation (Nasdaq: DRRX) today announced that Dr. James E. Brown, President and CEO, Michael H. Arenberg, Chief Financial Officer, and Dr. Norman Sussman, Chief Medical Officer will present at the H.C. Wainwright Bioconnect Conference which will be available on demand starting on January 10, 2022.

DURECT and Innocoll Announce a $136 Million U.S. Licensing Agreement for POSIMIR® (Bupivacaine Solution)
22 Dec, 2021 Yahoo! Finance

DURECT Corporation (Nasdaq: DRRX) today announced a licensing agreement granting Innocoll Biotherapeutics plc, a specialty pharmaceutical company and portfolio business of Gurnet Point Capital, exclusive development and commercialization rights to POSIMIR® (bupivacaine solution) for infiltration use, DURECT's FDA-approved non-opioid, sustained-release local analgesic for the treatment of post-surgical pain in adults following arthroscopic subacromial decompression surgery, in the United States.

Do Institutions Own DURECT Corporation (NASDAQ:DRRX) Shares?
22 Dec, 2021 Yahoo! Finance

If you want to know who really controls DURECT Corporation ( NASDAQ:DRRX ), then you'll have to look at the makeup of...

DURECT Corporation Expands Board of Directors with Appointment of Biopharmaceutical Industry Finance Veteran Peter Garcia
14 Dec, 2021 Yahoo! Finance

DURECT Corporation (Nasdaq: DRRX) today announced the expansion of its board of directors with the appointment of Peter García, a biopharmaceutical industry veteran with over 25 years of financial leadership experience.

DURECT Corporation to Participate in Alcoholic Liver Disease Workshop Today at the 5th Annual NASH Summit
29 Nov, 2021 Yahoo! Finance

DURECT Corporation (Nasdaq: DRRX) announced it will participate in a workshop today at the 5th Annual NASH Summit being held virtually from today through December 2, 2021.

Data Presentation Today at The Liver Meeting® 2021 Shows Increasing Hospital Admissions for Alcohol-Associated Hepatitis (AH) in the U.S.
12 Nov, 2021 Yahoo! Finance

DURECT Corporation (Nasdaq: DRRX) today announced the presentation of data at the American Association for The Study of Liver Diseases (AASLD) The Liver Meeting® 2021 showcasing an increase of hospitalizations for alcohol-associated hepatitis (AH) in the U.S. of approximately 19% (from 110,085 in 2015 to 131,510 in 2018) or approximately 4.8% per year between 2015 and 2018.

DURECT Corporation Doses First ex-U.S. Patient in Phase 2b AHFIRM Study of Larsucosterol (DUR-928) in Severe Alcohol-Associated Hepatitis
10 Nov, 2021 Yahoo! Finance

DURECT Corporation (Nasdaq: DRRX) today announced it dosed the first ex-U.S. patient in Australia as part of its AHFIRM randomized, double-blind, placebo-controlled, multi-center Phase 2b study to evaluate the safety and efficacy of larsucosterol in severe alcohol-associated hepatitis (AH) patients.

DURECT Corporation Announces Poster Presentation on the Prevalence of Hospitalized Alcohol-Associated Hepatitis (AH) Patients in the U.S. to be Presented at The Liver Meeting® 2021
08 Nov, 2021 Yahoo! Finance

DURECT Corporation (Nasdaq: DRRX) today announced that Suthat Liangpunsakul, M.D. will present a poster at the American Association for The Study of Liver Diseases (AASLD) The Liver Meeting® 2021 to be held virtually November 12-15, 2021.

Health Check: How Prudently Does DURECT (NASDAQ:DRRX) Use Debt?
07 Nov, 2021 Yahoo! Finance

The external fund manager backed by Berkshire Hathaway's Charlie Munger, Li Lu, makes no bones about it when he says...

Durect (DRRX) Reports Q3 Loss, Misses Revenue Estimates
02 Nov, 2021 Yahoo! Finance

Durect (DRRX) delivered earnings and revenue surprises of 0.00% and -0.46%, respectively, for the quarter ended September 2021. Do the numbers hold clues to what lies ahead for the stock?

DURECT Corporation Reports Third Quarter 2021 Financial Results and Update of Programs
02 Nov, 2021 Yahoo! Finance

DURECT Corporation (Nasdaq: DRRX) today announced financial results for the three months ended September 30, 2021 and provided a corporate update.

12 Health Care Stocks Moving In Friday's Intraday Session
29 Oct, 2021 FinancialContent

Gainers MiNK Therapeutics (NASDAQ:INKT) shares rose 16.88% to $16.96 during Friday's regular session. Vocera ...

DURECT Corporation to Announce Third Quarter 2021 Financial Results and Provide Business Update on November 2
26 Oct, 2021 Yahoo! Finance

DURECT Corporation (Nasdaq: DRRX) today announced that it will report its third quarter 2021 financial results and host a conference call after the market close on Tuesday, November 2, 2021.

Will Durect (DRRX) Report Negative Q3 Earnings? What You Should Know
25 Oct, 2021 Yahoo! Finance

Durect (DRRX) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

DURECT Corporation Fireside Chat at the H.C. Wainwright 5th Annual NASH Investor Conference
07 Oct, 2021 Yahoo! Finance

DURECT Corporation (Nasdaq: DRRX) today announced that Dr. James E. Brown, President and CEO, Michael H. Arenberg, Chief Financial Officer, Dr. Norman Sussman, Chief Medical Officer, and Dr. WeiQi Lin, Executive Vice President of R&D, will be participating in a fireside chat hosted by Ed Arce, Managing Director of Equity Research at H.C. Wainwright.

The Daily Biotech Pulse: Moderna Invests In Africa, Amgen Announces Neuroscience R&D Collaboration, Decision Day For Chemocentryx, Biophytis To Restate Results
07 Oct, 2021 FinancialContent

Here's a roundup of top developments in the biotech space over the last 24 hours: Scaling The Peaks (Biotech Stocks Hitting ...

The Daily Biotech Pulse: Takeda Suspends Studies On Safety Scare, Acer's Sleep Disorder Drug Filing Accepted For Review, Voyager's Licensing Options Deal
06 Oct, 2021 FinancialContent

Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peaks (Biotech Stocks Hitting ...

DURECT Corporation Fireside Chat at the Cantor Fitzgerald Global Healthcare Conference 2021
23 Sep, 2021 Yahoo! Finance

DURECT Corporation (Nasdaq: DRRX) today announced that Dr. James E. Brown, President and CEO, Michael H. Arenberg, Chief Financial Officer, Dr. Norman Sussman, Chief Medical Officer, and Dr. WeiQi Lin, Executive Vice President of R&D, will be participating in a fireside chat hosted by Kristen Kluska, Director, Equity Research Analyst at Cantor Fitzgerald.

DURECT Corporation Fireside Chat at Oppenheimer's Fall Healthcare Life Sciences & MedTech Summit
15 Sep, 2021 Yahoo! Finance

DURECT Corporation (Nasdaq: DRRX) today announced that Dr. James E. Brown, President and CEO, Michael H. Arenberg, Chief Financial Officer, Dr. Norman Sussman, Chief Medical Officer, and Dr. WeiQi Lin, Executive Vice President of R&D, will be participating in a fireside chat hosted by Francois Brisebois, Managing Director, Senior Biotechnology Research Analyst at Oppenheimer & Co. Inc.

DURECT Corporation Fireside Chat at the H.C. Wainwright Annual Global Investment Conference
07 Sep, 2021 Yahoo! Finance

DURECT Corporation (Nasdaq: DRRX) today announced that James E. Brown, President, CEO, Michael H. Arenberg, Chief Financial Officer, Dr. Norman Sussman, Chief Medical Officer and Dr. WeiQi Lin, Executive Vice President of R&D will be participating in a fireside chat hosted by Ed Arce of H.C. Wainwright, at the H.C. Wainwright 23rd Annual Global Investment Conference. A recording of the fireside chat will be available on-demand starting at 7:00 A.M. Eastern Standard Time on September 13, 2021.

The Daily Biotech Pulse: AzurRx Jumps On Data, Agios' Regulatory Application For Mitapivat Accepted For Priority Review, FDA Nod For GlaxoSmithKline
18 Aug, 2021 FinancialContent

Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peaks (Biotech Stocks Hitting ...

The Daily Biotech Pulse: Lilly Reorganizes Business Units In Neuroscience Focus, Helius Medical Spikes On Breakthrough Designation, Ra Medical Sells Dermatology Business
17 Aug, 2021 FinancialContent

Here's a roundup of top developments in the biotech space over the last 24 hours: Scaling The Peaks (Biotech Stocks Hitting ...

Would Shareholders Who Purchased DURECT's (NASDAQ:DRRX) Stock Year Be Happy With The Share price Today?
09 Aug, 2021 Yahoo! Finance

The simplest way to benefit from a rising market is to buy an index fund. When you buy individual stocks, you can make...

Durect (DRRX) Reports Q2 Loss, Misses Revenue Estimates
29 Jul, 2021 Yahoo! Finance

Durect (DRRX) delivered earnings and revenue surprises of 0.00% and -16.56%, respectively, for the quarter ended June 2021. Do the numbers hold clues to what lies ahead for the stock?

The Daily Biotech Pulse: Ardelyx Sinks On Regulatory Setback, AnPac Issues Positive Preannouncement, European Nod For Myovant, HCW Biologics Debuts On Wall Street
20 Jul, 2021 FinancialContent

Here's a roundup of top developments in the biotech space over the last 24 hours: Scaling The Peaks (Biotech Stocks Hitting ...

The Daily Biotech Pulse: Moderna To Join S&P 500 Index, Thumbs Down For FibroGen's Anemia Drug, Corvus Shelves COVID Study
16 Jul, 2021 FinancialContent

Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peaks (Biotech Stocks Hitting ...

The Daily Biotech Pulse: Galapagos Sinks On Data, J&J Recalls Sunscreen Products, FibroGen Awaits AdCom Verdict, 3 IPOs
15 Jul, 2021 FinancialContent

Here's a roundup of top developments in the biotech space over the last 24 hours: Scaling The Peaks (Biotech Stocks Hitting ...

DURECT Corporation (DRRX) is a NASDAQ Common Stock listed in , ,

970x250